Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ADX-038

Oligonucleotide (siRNA) · Gene silencing · developed by ADARx Pharmaceuticals

Phase 1/2 Most advanced trial

ADRX Developer

1 Registered trials

What is ADX-038?

ADX-038 is a siRNA duplex oligonucleotide being studied in paroxysmal nocturnal hemoglobinuria, IgA nephropathy, C3 glomerulopathy, and other complement-mediated kidney diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: siRNA
Drug type: Oligonucleotide (siRNA)
Mechanism: Gene silencing
Therapy area: Hematology, Immunology, Renal & urology
Developer: ADARx Pharmaceuticals, Inc. (ADRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06989359	Phase 2	IgAN	Recruiting	ADRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

C3GComplement-mediated Kidney DiseaseIC-MPGNIgA Nephropathy (IgAN)IgANParoxysmal Nocturnal Hemoglobinuria (PNH)

More from ADARx Pharmaceuticals

ADX-324 Phase 3 ADX-626 Phase 1 ADX-850 Phase 1

Sources

ClinicalTrials.gov NCT05876312

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADRX page.

Follow ADRX, the company behind ADX-038

See ADRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z